Back to Feed
总结
GSK宣布，其用于慢性乙型肝炎的反义寡核苷酸候选药物bepirovirsen在B‑Well 1与B‑Well 2两项Ⅲ期临床试验中取得积极结果，达到主要终点，显示部分患者可实现乙肝表面抗原持续下降并具备“功能性治愈”潜力。公司称将与合作方Ionis及监管机构沟通，推进后续数据披露与上市申报，若获批或为该领域首创新机制疗法。
正文
GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B GSK GSK hails promising trial results for hepatitis B treatment Financial Times GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push Fierce Biotech Ionis Pharmaceuticals Announces Positive Phase 3 Results for Bepirovirsen TradingView - Track All Markets GSK's Chronic Hepatitis B Drug Meets Primary Endpoints in Late-stage Studies 富途牛牛
发布时间：